Moderna (MRNA) PT Lowered to $348 at Piper Sandler, Following Earnings
Tweet
Share
E-mail
Get Alerts MRNA Hot Sheet
Price: $133.32 -23.55%
Rating Summary:
6 Buy, 21 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
6 Buy, 21 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Moderna (NASDAQ: MRNA) to $348.00 (from $445.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Moderna (MRNA) to Neutral
- Jefferies Downgrades Pop Mart International Group Ltd (9992:HK) to Hold
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Earnings, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
